DENVER, June 2, 2005 (PRIMEZONE) -- Medical International Technology, Inc. ("MIT") (OTCBB:MDIR) (http://www.mitcanada.ca), a developer and manufacturer of patented needle free jet injectors for human and animal inoculation, is pleased to announce the MedJet(r) Needle Free MBX Model Injector and its significant advantages in the treatment of palmar hyperhidrosis has been featured in the June edition of the Journal of the American Academy of Dermatology (JAAD).
GLOBALLY RECOGNIZED LEADING JOURNAL FOR DERMATOLOGICAL COMMUNITY
MIT is very pleased to have been featured in the JAAD and views this as a significant event for the Company. As the official publication of the American Academy of Dermatology, the Journal is dedicated to the clinical and continuing education needs of the entire dermatologic community and is internationally known as the leading journal in the field. Original, peer-reviewed articles cover clinical and investigative studies, treatments, new diagnostic techniques, and other topics relating to the prevention, diagnosis, and treatment of disorders of the skin. Included are CME articles based on the Core Curriculum of the American Academy of Dermatology. The Journal ranks in the top 4.3% of the 5,684 scientific journals most frequently cited (2000 Science Citation Index).
The article is titled: "Use of needle-free anesthesia in the treatment of palmar hyperhidrosis with botulinum A toxin."
ARTICLE CONTENTS
Pursuant to the Company's press release of April 25, 2005, Dr. Antranik Benohanian MD, FRCPC, Dermatologist at Saint-Luc Hospital of The Montreal University Hospital Centre, commenced testing of MIT's human injectors in his Hyperhidrosis studies. In addition to discussing how the MedJet(r) was used, the article also contains photos of the MedJet(r), photos of the minimal side effects experienced by participants, advantages of needle-free injections in treating palmar hyperhidrosis and ends with the following conclusion:
"In conclusion, this technique has the potential to replace peripheral nerve blockade prior to BTX-A injections for the treatment of palmar hyperhidrosis. It may also be used for plantar hyperhidrosis."
"We are extremely pleased that Dr. Benohanian's technique using MIT's MedJet(r) Needle Free Injector was featured in this prestigious journal," stated Karim Menassa, President and CEO of Medical International. "This further validates the MedJet(r) has potential applications in the treatment of Hyperhidrosis and other treatments across the World," added Mr. Menassa.
The article can be found at the following website: http://www.eblue.org/scripts/om.dll/serve?action=searchDB&searchDBfor=art&artType=full&id=as0190962204039532
This press release is available on the Medical International Investor Relations site for investor questions, commentary and feedback. Investors are asked to visit http://www.agoracom.com/IR/MIT . Alternatively, investors can e-mail their questions or comments directly to MDIR@agoracom.com or asked to be placed on the Medical International investor e-mail list to receive all future press releases directly.
About Medical International Technology, Inc. (http://www.mitcanada.ca)
MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.
The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology, Inc. takes no obligation to update or correct forward-looking statements.